BGLC 8-K
BioNexus Gene Lab Corp (BGLC)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of Company as specified in its charter) |
|
| |||
(State or other jurisdiction |
| (Commission |
| (IRS Employer |
of Incorporation) |
| File Number) |
| Identification Number) |
(Address of principal executive offices)
Phone: +1 (
(Company's Telephone Number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01. Regulation FD Disclosure.
Item 8.01. Other Events.
On March 11, 2026, the Company issued a Press Release which dislosed that, in connection with its Fidelion Diagnostics Pte. Ltd (“Fidelion”) transaction, Dr. Muthu Meyyappan has been appointed Chief Commercial Officer of Fidelion.
Dr. Meyyappan will lead Fidelion’s global commercial strategy and partnerships, including the development of clinical, laboratory, and pharmaceutical collaborations to support the adoption of advanced oncology diagnostic technologies across international markets.
Minimal residual disease (MRD) testing represents one of the fastest-growing segments of precision oncology diagnostics, as healthcare systems increasingly adopt genomic technologies to detect cancer recurrence earlier and guide more personalized treatment monitoring.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report. The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934.
Item 9.01. Financial Statement and Exhibits.
(d) Exhibits.
Exhibit No. |
| Description |
| ||
104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BioNexus Gene Lab Corp.
| /s/ Su-Leng Tan Lee |
|
By: | Su-Leng Tan Lee |
|
| Chief Executive Officer |
|
|
|
|
Date: | March 17, 2026 |
|
2 |
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of its VitaGuard™ MRD Platform
KUALA LUMPUR, MALAYSIA – March 11, 2026
BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its Fidelion Diagnostics Pte. Ltd (“Fidelion”) transaction, Dr. Muthu Meyyappan has been appointed Chief Commercial Officer of Fidelion. Fidelion is a precision diagnostics company focused on advancing next-generation oncology testing technologies, including minimal residual disease (MRD) liquid biopsy assays. Fidelion serves as the international intellectual property and commercialization vehicle for the VitaGuard™ MRD technology developed by Tongshu Gene, supporting commercialization initiatives outside Greater China. BGLC is a strategic investor in Fidelion and holds the exclusive commercialization rights for VitaGuard™ throughout Southeast Asia through its licensing arrangement with Fidelion.
Dr. Meyyappan will lead Fidelion’s global commercial strategy and partnerships, including the development of clinical, laboratory, and pharmaceutical collaborations to support the adoption of advanced oncology diagnostic technologies across international markets.
Minimal residual disease (MRD) testing represents one of the fastest-growing segments of precision oncology diagnostics, as healthcare systems increasingly adopt genomic technologies to detect cancer recurrence earlier and guide more personalized treatment monitoring.
Experienced Commercial Leader in Oncology Diagnostics
Dr. Meyyappan brings more than 15 years of global leadership experience in precision oncology diagnostics, genomics, and liquid biopsy commercialization.
He previously held senior commercial leadership roles at Menarini Silicon Biosystems, Congenica, Variantyx, and QIAGEN, where he worked on the commercialization and global expansion of genomic and oncology diagnostic platforms.
Most recently, Dr. Meyyappan served as Global Chief Commercial Officer where he helped expand Menarini’s oncology diagnostics business and supported the commercial adoption of liquid biopsy and MRD-related diagnostic platforms.
Earlier in his career, he served as Chief Commercial Officer at Variantyx, where he led the global commercial launch of the Genomic Unity® whole-genome sequencing platform.
Dr. Meyyappan holds a Ph.D. in Cancer Biology from the University of Calgary and a Bachelor of Science in Biotechnology from the Rochester Institute of Technology.
Strengthening Global Commercialization Strategy
Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp., commented:
“Dr. Meyyappan brings extensive experience in scaling oncology diagnostics and genomics businesses globally. His expertise in commercial strategy, partnerships, and market development will be instrumental as Fidelion continues to build the infrastructure required to support the global adoption of next-generation diagnostic technologies.”
Mr. Tan continued:
“BioNexus Gene Lab Corp.’s strategic investment in Fidelion, together with our Southeast Asia commercialization rights for VitaGuard™, positions us to support the regional expansion of advanced precision oncology diagnostics. The addition of experienced commercial leadership represents an important step in advancing this strategy.”
Expanding Access to Precision Oncology Diagnostics
Dr. Meyyappan commented:
“Advances in genomics and liquid biopsy technologies are transforming how cancer is detected and monitored. Fidelion is building a platform to support the commercialization of innovative diagnostic technologies, and I look forward to working with the team to expand partnerships with healthcare providers, laboratories, and pharmaceutical companies globally.”
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging technology platforms. Through strategic investments, partnerships, and licensing arrangements, the Company supports the development and commercialization of next-generation healthcare technologies.
For more information, please visit
www.bionexusgenelab.com
Investor Relations
BioNexus Gene Lab Corp.
Email: [email protected]
| 2 |
About Fidelion Diagnostics
Fidelion Diagnostics Pte. Ltd. is a precision diagnostics company focused on the global development and commercialization of advanced oncology testing technologies, including minimal residual disease (MRD) liquid biopsy assays.
For more information, please visit
www.fideliondx.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding commercialization initiatives, strategic partnerships, licensing arrangements, and the expected impact of executive leadership appointments.
Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that may affect future results include market adoption of diagnostic technologies, regulatory developments, strategic partnership outcomes, commercialization execution, and other risks detailed in the Company’s filings with the Securities and Exchange Commission.
BioNexus Gene Lab Corp. undertakes no obligation to update any forward-looking statements except as required by law.
| 3 |